Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$7.29 +0.8%	$6.53	$4.64 ▼ $61.90	$89.21M	3.19	203,183 shs	43,139 shs
CRDL Cardiol Therapeutics	$1.24 -3.4%	$1.04	$0.77 ▼ $3.12	$102.19M	0.98	362,033 shs	83,256 shs
TPST Tempest Therapeutics	$6.33 +0.4%	$7.47	$5.35 ▼ $47.45	$23.29M	-1.78	159,268 shs	10,671 shs
TVRD Cara Therapeutics	$29.97 -2.9%	$0.00	$8.13 ▼ $34.31	$93.36M	0.21	20,551 shs	15,674 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	-1.77%	-2.43%	-3.60%	-1.36%	-83.06%
CRDL Cardiol Therapeutics	+10.34%	+20.75%	+18.52%	+8.47%	-45.42%
TPST Tempest Therapeutics	+1.94%	0.00%	-19.54%	-38.72%	-84.86%
TVRD Cara Therapeutics	-7.58%	+3,085,999,900.00%	+3,085,999,900.00%	+3,085,999,900.00%	+3,085,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBP Corbus Pharmaceuticals	4.1071 of 5 stars	4.6	0.0	0.0	4.7	3.2	1.7	0.0
CRDL Cardiol Therapeutics	2.4499 of 5 stars	3.7	4.0	0.0	0.0	2.2	0.0	0.6
TPST Tempest Therapeutics	1.7414 of 5 stars	3.3	3.0	0.0	0.0	2.0	0.0	0.6
TVRD Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBP Corbus Pharmaceuticals	3.10	Buy	$50.88	597.87% Upside
CRDL Cardiol Therapeutics	3.40	Buy	$8.67	601.19% Upside
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	374.31% Upside
TVRD Cara Therapeutics	3.00	Buy	$65.00	116.88% Upside

Current Analyst Ratings Breakdown

Latest TPST, CRDL, TVRD, and CRBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	TVRD Cara Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/7/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/7/2025	CRBP Corbus Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$65.00 ➝ $58.00
5/7/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $56.00
5/7/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
4/16/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/10/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$16.00 ➝ $16.00
4/10/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Perform	$7.00 ➝ $9.00
4/7/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/28/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$169.00 ➝ $91.00
3/28/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$611.00 ➝ $208.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	($1.56) per share	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.32 per share	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$1.39 per share	N/A
TVRD Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBP Corbus Pharmaceuticals	-$44.60M	-$4.22	N/A	N/A	N/A	N/A	-42.28%	-32.92%	8/5/2025 (Estimated)
CRDL Cardiol Therapeutics	-$20.84M	-$0.34	N/A	N/A	N/A	N/A	-194.40%	-129.07%	7/14/2025 (Estimated)
TPST Tempest Therapeutics	-$29.49M	-$17.98	N/A	N/A	N/A	N/A	-187.44%	-82.61%	8/14/2025 (Estimated)
TVRD Cara Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest TPST, CRDL, TVRD, and CRBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	TPST Tempest Therapeutics	-$3.71	-$3.16	+$0.55	-$3.16	N/A	N/A
5/6/2025	Q1 2025	CRBP Corbus Pharmaceuticals	-$1.26	-$1.39	-$0.13	-$1.39	N/A	N/A
3/31/2025	Q4 2024	CRDL Cardiol Therapeutics	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A
3/27/2025	Q4 2024	TPST Tempest Therapeutics	-$3.12	-$4.03	-$0.91	-$0.31	N/A	$0.49 million
3/11/2025	Q4 2024	CRBP Corbus Pharmaceuticals	-$1.02	-$0.78	+$0.24	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A
TVRD Cara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBP Corbus Pharmaceuticals	N/A	13.84	13.84
CRDL Cardiol Therapeutics	0.01	2.49	2.49
TPST Tempest Therapeutics	N/A	1.69	1.69
TVRD Cara Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBP Corbus Pharmaceuticals	64.64%
CRDL Cardiol Therapeutics	12.49%
TPST Tempest Therapeutics	22.52%
TVRD Cara Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
CRBP Corbus Pharmaceuticals	4.00%
CRDL Cardiol Therapeutics	5.25%
TPST Tempest Therapeutics	4.70%
TVRD Cara Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBP Corbus Pharmaceuticals	40	12.24 million	11.69 million	Optionable
CRDL Cardiol Therapeutics	20	82.61 million	78.27 million	Not Optionable
TPST Tempest Therapeutics	20	3.68 million	41.59 million	Optionable
TVRD Cara Therapeutics	80	3.12 million	N/A	N/A

TPST, CRDL, TVRD, and CRBP Headlines

Recent News About These Companies

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27 at 8:00 AM | businesswire.com

Cara Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen

May 27 at 1:15 AM | americanbankingnews.com

Cara Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Oppenheimer

May 26 at 6:10 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST, CRDL, TVRD, and CRBP Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

$7.29 +0.06 (+0.83%)

As of 11:36 AM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Cardiol Therapeutics NASDAQ:CRDL

$1.24 -0.04 (-3.44%)

As of 11:36 AM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Tempest Therapeutics NASDAQ:TPST

$6.32 +0.03 (+0.40%)

As of 11:29 AM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Cara Therapeutics NASDAQ:TVRD

$29.97 -0.89 (-2.88%)

As of 11:03 AM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time